title: Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
abstract: During the past half-decade, clinical trials have permitted major progress in treatment of metastatic renal cell carcinoma with the first generation of targeted therapies (bevacizumab, sunitinib, sorafenib, everolimus, and temsirolimus). New targeted agents such as axitinib, tivozanib, and dovitinib, all of which are tyrosine kinase inhibitors, have been developed in treatment of metastatic renal cell carcinoma. In the same time, more information regarding mechanism of disease and drug resistance shed light on new targets and new potent agents. We report an overview of the more relevant data published over the past year, which may modify the therapeutic landscape of kidney cancer in the near future.
authors.affiliation: Centre Hospitalo-Universitaire, Hôpital Saint André, Bordeaux, France. marine.gross-goupil@chu-bordeaux.fr
authors.forename: Marine
authors.initials: M
authors.lastname: Gross-Goupil
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
authors.forename: Alain
authors.initials: A
authors.lastname: Ravaud
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends*; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor